Primecap Management Co. CA Invests $1.12 Billion in Elanco Animal Health Incorporated $ELAN

Primecap Management Co. CA acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 45,445,012 shares of the company’s stock, valued at approximately $1,118,402,000. Primecap Management Co. CA owned approximately 9.10% of Elanco Animal Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Elanco Animal Health during the 1st quarter worth approximately $2,065,000. Goldman Sachs Group Inc. increased its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after acquiring an additional 295,651 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Harrington purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director directly owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 63,198 shares of company stock valued at $1,473,109 in the last 90 days. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $25.11 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock has a 50 day moving average price of $24.58 and a 200 day moving average price of $24.01. The stock has a market capitalization of $12.55 billion, a PE ratio of -61.25, a price-to-earnings-growth ratio of 1.46 and a beta of 1.67. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm earned $0.26 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ELAN. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen boosted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. UBS Group upped their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, KeyCorp lifted their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.